Anne Wojcicki, 23andMe CEO (Jordan Vonderhaar/Bloomberg via Getty Images)
23andMe to shut down its therapeutics division
23andMe is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company said Monday evening.
The company said it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.